ストックスクリーナーアプリを入手
1.70
0.00%
0.00
アフターアワーズ：
1.74
0.04
+2.35%
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
Investment Review: Should I invest in Milestone Pharmaceuticals Inc before earningsQuarterly Profit Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Milestone Pharmaceuticals (MIST) Highlights Etripamil's Safety a - GuruFocus
Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - Bitget
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times
FDA-approved PSVT nasal spray shows minimal blood pressure change - Stock Titan
Boxer Capital Management LLC Invests $1.33 Million in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality - Seeking Alpha
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals Sets March 20 Call for 2025 Results and Business Update - TipRanks
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - Bitget
Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan
Swing Trade: What is the long term forecast for Milestone Pharmaceuticals Inc stockWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Wells Fargo Initiates Coverage of Milestone Pharmaceuticals (MIST) with Overweight Recommendation - MSN
Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Stock Report: Does Milestone Pharmaceuticals Inc have consistent dividend growthRecession Risk & Safe Entry Point Alerts - baoquankhu1.vn
Earnings Report: Should I invest in Milestone Pharmaceuticals Inc before earningsShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - MSN
Milestone Pharmaceuticals Inc. $MIST Shares Purchased by Propel Bio Management LLC - MarketBeat
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Thursday - MarketBeat
MIST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Trend Review: Can Milestone Pharmaceuticals Inc beat the S P 500Earnings Growth Report & Expert Curated Trade Setups - baoquankhu1.vn
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update - MarketBeat
Aug Outlook: Can Milestone Pharmaceuticals Inc beat the S P 500Portfolio Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Milestone Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Zacks Research Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold - MarketBeat
BlackRock HPS Credit Strategies Fund's Milestone Pharmaceuticals Inc(MIST) Holding History - GuruFocus
Risk Recap: What is the long term forecast for Milestone Pharmaceuticals Inc stockJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Does Milestone Pharmaceuticals Inc. have consistent dividend growthQuarterly Investment Review & AI Powered Buy and Sell Recommendations - mfd.ru
What is Milestone Pharmaceuticals Inc.’s book value per shareJuly 2025 Retail & Capital Efficient Trade Techniques - mfd.ru
Is Milestone Pharmaceuticals Inc.’s ROIC above industry average2025 Top Gainers & Safe Entry Trade Signal Reports - mfd.ru
Milestone Pharmaceuticals - WCIV
Why Milestone Pharmaceuticals Inc. stock is a value investor pick2025 Bull vs Bear & Community Consensus Trade Signals - mfd.ru
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
MIST Should I Buy - Intellectia AI
Milestone Appoints David Sandoval as General Counsel - Intellectia AI
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Will Milestone Pharmaceuticals Inc. stock split attract more investorsMarket Growth Report & Real-Time Buy Signal Notifications - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
What are the risks of holding Milestone Pharmaceuticals Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com Australia
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com Nigeria
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) CFO updates 204,000-share option to $1.96 - Stock Titan
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 133,054 Shares - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):